# A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

> **NCT02107963** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Sarcoma
- Osteosarcoma
- Neuroblastoma
- Melanoma

## Interventions

- **BIOLOGICAL:** Anti-GD2-CAR engineered T cells
- **DRUG:** AP1903
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02107963
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-28
- **Primary completion:** 2016-08-15
- **Final completion:** 2017-01-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107963, "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02107963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*